Immix Biopharma Inc
IMMX2.540USD
-0.110-4.15%
Cierre 08/04, 16:00（ET）Cotizaciones retrasadas 15 min
70.74MCap. mercado
PérdidaP/E TTM
Más Datos de Immix Biopharma Inc Compañía
Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the application of chimeric antigen receptor cell therapy (CAR- T) in light chain (AL) Amyloidosis and autoimmune disease. The Company's lead cell therapy asset is CAR-T NXC-201 for autoimmune disease, relapsed/refractory AL Amyloidosis, and relapsed/refractory multiple myeloma, which is being evaluated in its ongoing Phase Ib/IIa NEXICART-1 (NCT04720313) clinical trial. Its tissue specific therapeutic IMX-110 is in clinical trials as a monotherapy, and in combination with tislelizumab (BeiGene anti-PD-1 - IMMINENT-01 NCT05840835) for advanced solid tumors, such as relapsed/refractory colorectal cancer (CRC). IMX-110 in Phase Ib/IIa clinical trials, is a Tissue-Specific Therapeutic with TME Normalization, a technology that the Company is developing initially for mCRC and Soft Tissue Sarcoma (STS).
Información de la empresa
Símbolo de cotizaciónIMMX
Nombre de la empresaImmix Biopharma Inc
Fecha de salida a bolsaDec 16, 2021
Director ejecutivoDr. Ilya Rachman, M.D., Ph.D.
Número de empleados18
Tipo de seguridadOrdinary Share
Fin del año fiscalDec 16
Dirección11400 West Olympic Blvd.
CiudadLOS ANGELES
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal90064
Teléfono18889581084
Sitio Webhttps://immixbio.com/
Símbolo de cotizaciónIMMX
Fecha de salida a bolsaDec 16, 2021
Director ejecutivoDr. Ilya Rachman, M.D., Ph.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Jason Hsu, Ph.D.
Mr. Jason Hsu, Ph.D.
Independent Director
Independent Director
4.86M
--
Ms. Helen C. Adams, CPA
Ms. Helen C. Adams, CPA
Lead Independent Director
Lead Independent Director
174.75K
-0.13%
Dr. Magda Marquet, Ph.D.
Dr. Magda Marquet, Ph.D.
Independent Director
Independent Director
173.19K
+161.79%
Mr. Gabriel Morris
Mr. Gabriel Morris
Chief Financial Officer, Director
Chief Financial Officer, Director
--
--
Dr. Graham Ross
Dr. Graham Ross
Acting Chief Medical Officer, Head - Clinical Development
Acting Chief Medical Officer, Head - Clinical Development
--
--
Ms. Jane M. Buchan, Ph.D.
Ms. Jane M. Buchan, Ph.D.
Independent Director
Independent Director
--
--
Dr. Ilya Rachman, M.D., Ph.D.
Dr. Ilya Rachman, M.D., Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Mr. Carey Ng, Ph.D.
Mr. Carey Ng, Ph.D.
Independent Director
Independent Director
--
--
Dr. Vladimir Torchilin, Ph.D.
Dr. Vladimir Torchilin, Ph.D.
Scientific Co-Founder
Scientific Co-Founder
--
--
Ms. Yekaterina (Katie) Chudnovsky, J.D.
Ms. Yekaterina (Katie) Chudnovsky, J.D.
Independent Director
Independent Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Jason Hsu, Ph.D.
Mr. Jason Hsu, Ph.D.
Independent Director
Independent Director
4.86M
--
Ms. Helen C. Adams, CPA
Ms. Helen C. Adams, CPA
Lead Independent Director
Lead Independent Director
174.75K
-0.13%
Dr. Magda Marquet, Ph.D.
Dr. Magda Marquet, Ph.D.
Independent Director
Independent Director
173.19K
+161.79%
Mr. Gabriel Morris
Mr. Gabriel Morris
Chief Financial Officer, Director
Chief Financial Officer, Director
--
--
Dr. Graham Ross
Dr. Graham Ross
Acting Chief Medical Officer, Head - Clinical Development
Acting Chief Medical Officer, Head - Clinical Development
--
--
Ms. Jane M. Buchan, Ph.D.
Ms. Jane M. Buchan, Ph.D.
Independent Director
Independent Director
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: jue., 15 de may
Actualizado: jue., 15 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Hsu (Jason)
17.45%
GKCC, LLC
11.64%
Rachman (Ilya M)
4.09%
Ng (Carey)
3.75%
Bleichroeder LP
3.05%
Other
60.03%
Accionistas
Accionistas
Proporción
Hsu (Jason)
17.45%
GKCC, LLC
11.64%
Rachman (Ilya M)
4.09%
Ng (Carey)
3.75%
Bleichroeder LP
3.05%
Other
60.03%
Tipos de accionistas
Accionistas
Proporción
Individual Investor
28.71%
Corporation
11.64%
Investment Advisor/Hedge Fund
7.98%
Investment Advisor
4.27%
Research Firm
0.06%
Venture Capital
0.05%
Other
47.29%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
65
14.67M
52.67%
-1.12M
2025Q1
66
14.50M
53.34%
-1.02M
2024Q4
67
14.42M
52.43%
-1.29M
2024Q3
66
15.60M
56.77%
-243.92K
2024Q2
66
15.89M
59.32%
-308.72K
2024Q1
64
15.43M
77.52%
+5.90M
2023Q4
57
11.10M
62.12%
+3.00M
2023Q3
52
12.47M
73.23%
+2.63M
2023Q2
46
9.35M
66.71%
-203.85K
2023Q1
40
9.11M
65.58%
-364.69K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Hsu (Jason)
4.86M
17.45%
--
--
Apr 22, 2025
GKCC, LLC
3.24M
11.64%
--
--
Apr 22, 2025
Rachman (Ilya M)
1.14M
4.09%
+2.18K
+0.19%
Jun 18, 2025
Ng (Carey)
1.05M
3.75%
--
--
Apr 22, 2025
Bleichroeder LP
850.00K
3.05%
--
--
Mar 31, 2025
Cable Car Capital LLC
779.36K
2.8%
-16.74K
-2.10%
Mar 31, 2025
The Vanguard Group, Inc.
698.54K
2.51%
--
--
Mar 31, 2025
Morris (Gabriel S)
583.04K
2.09%
+2.23K
+0.38%
Jun 18, 2025
Lynwood Capital Management Inc.
405.00K
1.45%
+405.00K
--
Mar 31, 2024
Adams (Helen C)
174.75K
0.63%
-227.00
-0.13%
Apr 22, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
iShares Micro-Cap ETF
0.01%
Dimensional US Core Equity 1 ETF
0%
iShares Micro-Cap ETF
Proporción0.01%
Dimensional US Core Equity 1 ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
